No data are present in the literature about the effect of cytokines on the prototype b chemokine (C-C motif) ligand 2 (CCL2) or of peroxisome proliferator-activated receptor a (PPARa (PPARA)) activation on CCL2 and CXCL10 chemokines secretion in fibroblasts or preadipocytes in Graves' ophthalmopathy (GO). We have tested the effect of interferon g (IFNg (IFNG)) and tumor necrosis factor a (TNFa) on CCL2, and for comparison on the prototype a chemokine (C-X-C motif) ligand 10 (CXCL10), and the possible modulatory role of PPARa activation on secretion of these chemokines in normal and GO fibroblasts or preadipocytes in primary cell cultures. This study shows that IFNg alone, or in combination with TNFa, stimulates the secretion of CCL2 in primary orbital fibroblasts or preadipocytes from patients with GO at levels similar to those observed in controls. IFNg and TNFa also stimulated CXCL10 chemokine secretion as expected. The presence of PPARa and PPARg (PPARG) in primary fibroblasts or preadipocytes of patients with GO has been confirmed. PPARa activators were able to inhibit the secretion of CXCL10 and CCL2, while PPARg activators were confirmed to be able to inhibit CXCL10 but had no effect on CCL2. PPARa activators were stronger inhibitors of chemokine secretions than PPARg agonists. In conclusion, CCL2 and CXCL10 are modulated by IFNg and TNFa in GO. PPARa activators inhibit the secretion of the main prototype a (CXCL10) and b (CCL2) chemokines in GO fibroblasts or preadipocytes, suggesting that PPARa may be involved in the modulation of the immune response in GO.
Introduction
Recent evidences have shown that CXC a-chemokines (Th1), especially CXCL9, CXCL10, and CXCL11, play an important role in the initial phases of autoimmune thyroid dysfunction (Garcià-Lòpez et al. 2001 , Antonelli et al. 2004 , 2006a ,b, 2007 .
We have recently demonstrated that the secretion of CXCL9, CXCL10, and CXCL11 in primary cultures of Graves' ophthalmopathy (GO) fibroblasts and preadipocytes can be stimulated by interferon g (IFNg (IFNG)) and tumor necrosis factor a (TNFa; Antonelli et al. 2006c Antonelli et al. , 2009a , suggesting that GO retro-orbital cells participate in the selfperpetuation of inflammation by releasing chemokines (under the influence of cytokines) and inducing the recruitment of activated T cells in the orbit.
Furthermore, other studies have demonstrated recently a possible role for chemokine (C-C motif) ligand 2 (CCL2; also known as monocyte chemoattractant protein-1 (MCP1)) in GO. Hwang et al. (2009) showed that orbital fibroblasts from patients with GO overexpress CD40 and that CD154 (the ligand for CD40) upregulated the expression of CCL2. Furthermore, Chen et al. (2008) found that the expression of CCL2 was higher in the orbital fat of GO patients than in controls.
The peroxisome proliferator-activated receptors a (PPARa (PPARA)), PPARg (PPARG), and PPARd (PPARD) are ligand-activated nuclear receptors with a wide range of effects on metabolism, cell proliferation, and differentiation (Michalik et al. 2006) . In addition, abundant evidence suggests that the PPARs are also important regulators of the immune system. Of considerable interest, ligands for PPARg and PPARa have therapeutic activity in several rodent models of inflammatory and autoimmune diseases (Spencer et al. 1997 , Delerive et al. 2000 , Lovett-Racke et al. 2004 , Okamoto et al. 2005 , Lee et al. 2007 , Oliveira et al. 2007 , suggesting that they might have similar activity in human disease as well.
About chemokines, it has been recently shown that fenofibrate represses interleukin 17 (IL17 (IL17a)) and IFNg expression and improves colitis in Il10-deficient mice by inhibiting the expression of the gene-encoding chemokine (C-X-C motif) ligand 10 (CXCL10) and by repressing CXCL10 gene promoter activity in TNFa-treated HT-29 cells (Lee et al. 2007) .
Treatment of fibroblasts and preadipocytes with PPARg activators (rosiglitazone and pioglitazone) at neartherapeutic doses significantly inhibited IFNg-stimulated CXC chemokine secretion, strongly suggesting that PPARg might be involved in the regulation of IFNg-induced chemokine expression in human thyroid autoimmunity and GO (Antonelli et al. 2006c (Antonelli et al. , 2009a . More recently, we have shown that CXCL9 and CXCL11 chemokines are modulated by PPARa agonist secretion in Graves' and normal thyrocytes (Antonelli et al. 2010) . Furthermore, PPARa has been found to be expressed in fibroblasts (Pasquali et al. 2004 ) and preadipocytes (Antonelli et al. 2012) in GO patients.
However, until now, to our knowledge, no data are present in the literature about the effect of cytokines on CCL2 in GO or of PPARa activation on CCL2 and CXCL10 chemokine secretions in fibroblasts and preadipocytes in GO. Here, we have tested the effects of IFNg and TNFa on CCL2 (the prototype Th2 chemokine) and the possible modulatory role of PPARa activation on CCL2, and for comparison on the prototype Th1 CXCL10 chemokine, secretion in GO fibroblasts or preadipocytes in primary culture.
Materials and Methods

Fibroblast and preadipocyte cell cultures
Orbital adipose/connective tissue samples were obtained from five euthyroid patients (two on L-thyroxine after thyroidectomy) undergoing orbital decompression for severe GO during the inactive phase of the disease (all previously treated with antithyroid medication and systemic corticosteroids; none treated with orbital radiotherapy). All subjects gave their informed consent to the study, which was approved by the local Ethics Committee.
GO tissue explants were minced and placed directly in plastic culture dishes, to let preadipocyte fibroblasts proliferate, as described previously (Bahn et al. 1989) . Cells were propagated in medium 199 with 20% v/v fetal bovine serum (FBS; Gibco; Invitrogen Ltd.), penicillin (100 IU/ml), and gentamicin (20 mg/ ml) in a humidified 5% CO 2 incubator at 37 8C and maintained with medium 199 containing 10% FBS and antibiotics. Orbital cells were grown to confluence in six-well plates in medium 199 with 10% FBS in order to initiate adipocyte differentiation, which was carried out as reported previously (Antonelli et al. 2006c (Antonelli et al. , 2010 . The differentiation protocol was continued for 10 days, and the medium was replaced every 3-4 days. Separately, fibroblasts obtained from the same patients' orbital tissues were maintained for the same period in the medium lacking various components necessary for complete adipocyte differentiation (i.e. cPGI2, dexamethasone, and IBMX, 3-isobuty1-1-methylxanthine; Antonelli et al. 2010) . Control fibroblasts and preadipocytes were obtained from dermal tissues (not affected by any pathology) of the same patients.
Orbital preadipocyte fibroblast cultures were plated in medium 199 with 10% FBS, grown to confluence, and subjected to either the differentiation protocol or the nondifferentiation conditions. Cells were washed, stained with filtered 0 . 21% Oil Red O and subsequently with Mayer's hematoxylin solution (MHS-32; Sigma), and visualized using an Olympus IX50 light microscope and photographed at !20 as previously reported (Antonelli et al. 2009a (Antonelli et al. , 2012 .
CXCL10 and CCL2 secretion assays
For CXCL10 and CCL2 secretion assays, cells were seeded in 96-well plates at a concentration of 30 000 cells/ml as previously reported (Antonelli et al. 2009a ) and incubated (24 h) with IFNg (500, 1000, 5000, and 10 000 IU/ml; R&D Systems, Minneapolis, MN, USA) and 10 ng/ml TNFa (R&D Systems), alone or in combination (Antonelli et al. 2009a (Antonelli et al. , 2012 . After 24 h, the supernatant was collected and kept frozen at K20 8C until CXCL10 assay.
To establish how the PPARa or PPARg activators affect IFNg-induced chemokine secretion, cells were treated (24 h) with IFNg (1000 IU/ml) and TNFa (10 ng/ml) in the presence or absence of increasing concentrations of PPARa agonists (5, 10, 50, and 100 mmol/l fenofibrate; 50, 100, 200, and 400 mmol/l gemfibrozil or ciprofibrate; Sigma-Aldrich Corp.) or PPARg agonists (0, 1, 5, 10, and 20 mmol/l rosiglitazone; Glaxo SmithKline, or pioglitazone; Alexis Biochemicals, Lausen, Switzerland; Antonelli et al. 2012) .
Supernatants were assayed by ELISA for CXCL10 and CCL2 concentrations. The experiments were repeated three times with the different cell preparations.
Cell cultures and PPARa or PPARg agonist treatment
Cell cultures were treated (24 h) with PPARg agonists (0, 1, 5, 10, or 20 mmol/l rosiglitazone or pioglitazone) or PPARa agonists (5, 10, 50, and 100 mmol/l fenofibrate; 50, 100, 200, and 400 mmol/l gemfibrozil or ciprofibrate). Control cultures were grown (24 h) in the same medium containing vehicle (absolute ethanol, 0 . 47% v/v) without PPARa or PPARg agonists. Some cultures were examined by phase contrast microscopy using an Olympus IX50 light microscope.
Lysis and homogenization of cell preparations were performed, and the sample was immediately assayed for its protein concentration by conventional methods (Antonelli et al. 2006c) .
ELISA for CXCL10 and CCL2
Culture supernatants CXCL10 and CCL2 levels were assayed by a quantitative sandwich immunoassay using a commercially available kit (R&D Systems). The mean minimum detectable dose for CXCL10 was 1 . 35 pg/ml; the intra-and inter-assay coefficients of variation (CV) were 3 . 1 and 6 . 8% respectively. The mean minimum detectable dose for CCL2 was 4 . 6 pg/ml; the intra-and interassay CV were 4 . 6 and 5 . 7% respectively.
RT-PCR for PPARa and PPARg
Total RNA (400 ng) was reverse transcribed using TaqMan RT reagents kit as previously reported (Antonelli et al. 2010) . Primers and probes for PPARa and PPARg were from Applied Biosystems (TaqMan Gene Expression Assay; Hs00231882_m1 and Hs00234592_m1 respectively).
The amount of target, normalized to the endogenous reference glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Pre-Developed TaqMan Assay Reagents; Applied Biosystems) and relative to a calibrator (quantitative PCR human reference total RNA), was given by 2 KDDC t calculation (Antonelli et al. 2010) .
Data analysis
Values are given as meanGS.D. for normally distributed variables (in text), or meanGS.E.M. (in figures), otherwise as median and (interquartile range). Mean group values were compared using ANOVA for normally distributed variables, otherwise by the Mann-Whitney U (two groups) or Kruskal-Wallis (three groups or more) tests. Proportions were compared by the c 2 test. Post hoc comparisons on normally distributed variables were carried out using the Bonferroni-Dunn test.
Results
PPARa and PPARg expression in GO fibroblasts and preadipocytes
PPARa and PPARg mRNAs were detectable in all primary orbital fibroblast cells. According to RT-PCR results, the relative level of PPARa expression vs the reference gene (GAPDH) ranges from 0 . 4 to 0 . 9 and the expression of PPARg from 0 . 1 to 0 . 2. The results obtained in control fibroblasts are summarized in Table 1 . PPARa and PPARg were expressed by RT-PCR more in GO fibroblasts than in controls. Similar results were present in preadipocytes (data not shown).
PPAR agonists and chemokines in GO fibroblasts and preadipocytes CXCL10 was undetectable in the supernatants collected from primary GO fibroblast cultures. IFNg dose dependently induced the CXCL10 release (ANOVA, P!0 . 001; Table 2 ); similar results were observed in preadipocytes (ANOVA, P!0 . 001). TNFa alone had no effect (chemokines remaining undetectable), while the combination of IFNg and TNFa had a significant synergistic effect on the CXCL10 secretion both in fibroblasts (ANOVA, P!0 . 0001) and in preadipocytes (ANOVA, P!0 . 0001).
Treating GO fibroblasts or preadipocytes with rosiglitazone or pioglitazone, together with IFNg and TNFa stimulation, CXCL10 release was dose dependently inhibited (ANOVA, P!0 . 0001) as expected (Antonelli et al. 2006c (Antonelli et al. , 2009a .
By treating GO fibroblasts with fenofibrate (Fig. 1A) , gemfibrozil (Fig. 1B) , or ciprofibrate (Fig. 1C) , together with IFNg and TNFa stimulation, CXCL10 release was dose dependently inhibited. Similar results were observed in preadipocytes, in which fenofibrate, ciprofibrate, or gemfibrozil, dose dependently inhibited the IFNg-and TNFastimulated CXCL10 release (ANOVA, P!0 . 0001; data not shown).
The inhibition of the CXCL10 chemokine secretion induced by PPARa agonists, at the highest dosage, was stronger than that induced by PPARg activators both in fibroblasts ( Fig. 2A ) and in preadipocytes (Fig. 2B) . However, the relative potency of the PPARa agonists on the inhibition of the CXCL10 chemokine was different for each compound.
CCL2 was detectable (546G93 pg/ml) in the supernatants collected from primary GO fibroblast or preadipocyte cultures (751G106 pg/ml). IFNg dose dependently induced CCL2 release in fibroblasts (CCL2: 546G93, 723G85, 970G65, 1076G131, and 1204G171 pg/ml, respectively, with IFNg: 0, 500, 1000, 5000, and 10 000 IU/ml; ANOVA, Table 2 In fibroblasts, from patients with Graves' ophthalmopathy (GO), interferon g (IFNg) dose dependently induced the CXCL10 release (ANOVA, P!0 . 001); similar results were observed in preadipocytes (ANOVA, P!0 . 001). Tumor necrosis factor a (TNFa) alone had no effect (chemokines remaining undetectable), while the combination of IFNg and TNFa had a significant synergistic effect on the CXCL10 secretion both in fibroblasts (ANOVA, P!0 . 0001) and in preadipocytes (ANOVA, P!0 . 001) 1123G125, 1411G147, and 1504G168 pg/ml, respectively, with IFNg: 0, 500, 1000, 5000, and 10 000 IU/ml; ANOVA, P!0 . 001). TNFa alone had no effect on CCL2 release (with TNFa: 0, 1, and 10 ng/ml). The combination of IFNg and TNFa had a significant synergistic effect on CCL2 secretion (ANOVA, P!0 . 0001; Fig. 3 ) in primary GO fibroblasts (Fig. 3A ) and in preadipocytes (Fig. 3B) . Treating orbital fibroblasts with fenofibrate ( Fig. 4A) , gemfibrozil (Fig. 4B ), or ciprofibrate (Fig. 4C) , together with IFNg and TNFa stimulation, CCL2 release was dose dependently inhibited. Similar results were observed in preadipocytes, in which fenofibrate, gemfibrozil, or ciprofibrate dose dependently inhibited the IFNg-and TNFa-stimulated CXCL10 release (ANOVA, P!0 . 0001; data not shown).
The inhibition of the CCL2 chemokine secretion induced by PPARa agonists at the highest dosage in GO fibroblasts averaged 65% (Fig. 5A) . Treating orbital fibroblasts (Fig. 5A) or preadipocytes (Fig. 5B) A ANTONELLI and others . CCL2, CXCL10, and PPARa in GO together with IFNg and TNFa stimulation, had no significant effect on the CCL2 release. Rosiglitazone or pioglitazone, fenofibrate, ciprofibrate, or gemfibrozil alone had no effect and did not affect cell viability or total protein content (data not shown). The data obtained with orbital fibroblasts or preadipocytes were not significantly different from those obtained with control fibroblasts or preadipocytes (data not shown).
Discussion
This study shows that IFNg alone, or in combination with TNFa, stimulated the secretion of the CC chemokine CCL2 in primary orbital fibroblasts or preadipocytes from patients with GO. IFNg and TNFa stimulated the CXC chemokine secretion as expected. The presence of PPARa in primary fibroblasts or preadipocytes from patients with GO has been confirmed (Antonelli et al. 2012) . PPARa activators inhibited the secretion of both CXC (CXCL10) and CC chemokines (CCL2), while PPARg activators were confirmed to inhibit CXC chemokines but had no effect on CCL2. PPARa activators were stronger inhibitors of chemokine secretions than PPARg agonists.
Recently, some studies have suggested a possible role for CCL2 in GO. Hwang et al. (2009) CCL2. Furthermore, Chen et al. (2008) found that the expression of CCL2 was higher in GO orbital fat than in the orbital fat of controls and suggested that macrophage infiltration may play an important role in the pathogenesis of GO via overexpression of CCL2.
Our results show that CCL2 chemokine was secreted basally by normal fibroblasts or preadipocytes such as those from GO, responded to IFNg alone, and a synergistic action of IFNg in combination with TNFa was observed inducing the secretion of the chemokine in primary fibroblasts or preadipocytes from patients with GO. This last result is unexpected because Th2 chemokines are poor responders to IFNg, but it is in agreement with the results obtained by other studies on murine (Yamana et al. 2009 ) and human fibroblasts (Struyf et al. 1998) .
The fact that CCL2 can be produced by GO fibroblasts or preadipocytes, under the influence of cytokines such as IFNg or TNFa (released by activated Th1 lymphocytes), suggests a possible role of these cells on recruitment of monocytes and T lymphocytes to the tissue from the blood in GO.
IFNg and TNFa also stimulated CXC chemokine secretion as expected (Antonelli et al. 2006c (Antonelli et al. , 2009a . These results, on the whole, are in agreement with the view that autoimmune disorders evolve from an initial Th1 phase to a later Th2 prevalent immune response with progression toward fibrosis (Romagnani 1997 , Antonelli et al. 2008 . For example, the early expression of CXCL10 and CCL2 suggests their involvement in the initiation and perpetuation of disease in severe granulomatous experimental autoimmune thyroiditis, which progresses to fibrosis .
PPARa has been confirmed to be expressed more in GO fibroblasts or preadipocytes than in controls. These results are in agreement with our data (Antonelli et al. 2012 ) and the ones obtained by Pasquali et al. (2004) . In our studies, no significant adipocyte change was observed in fibroblasts after a 24 h incubation period with PPARa, according to the results obtained by Pasquali et al. (2004) that showed that few subpopulations (1-2%) of fibroblasts from Graves' ophthalmopathy (FGOs) exposed to fenofibrate changed their typical fibroblastic appearance after 24 h, such as in controls. Our results suggest that PPARa agonists are able to modulate both the Th1 and Th2 immune responses as suggested by their powerful action on the inhibition of chemokines. In fact, PPARa can modulate both CXC (CXCL10) and CC (CCL2) chemokines.
The anti-inflammatory action of PPARa has been widely investigated by many studies, and some studies advocate PPARa agonists as therapy for autoimmune disease (Cuzzocrea et al. 2004 , Gervois et al. 2004 , Lovett-Racke et al. 2004 , Lo Verme et al. 2005 , Okamoto et al. 2005 , Lee et al. 2007 , Oliveira et al. 2007 . The effect of PPARa on CXC chemokines has been less deeply investigated. In the study by Lee et al. (2007) , fenofibrate repressed the expression of the gene encoding CXCL10 and repressed CXCL10 gene promoter activity in TNFa-treated HT-29 cells. Our results are in agreement with a previous study that has demonstrated that CXCL9 and CXCL11 chemokines are modulated by PPARa agonists in Graves' and normal thyrocytes (Antonelli et al. 2010) .
The results of this study shed new light on the effect of PPARa on CXC chemokines, demonstrating a powerful effect on the secretion of CXCL10 both in normal fibroblasts and in preadipocytes, such as in cells obtained by GO, inhibiting the stimulatory effect of IFNg and TNFa on the secretion of these chemokines. Interestingly, the effect of PPARa has been exerted at near-therapeutic doses as also suggested by the study of Lovett-Racke et al. (2004) . The potency of the PPARa agonist used is maximum on the secretion of CXCL10 reaching about a 60% of inhibition by fenofibrate, while about a 40-50% of inhibition was observed with the others. This may suggest that the different PPARa agonist compounds may act through different pathways that remain to be explored. In the study by Lee et al. (2007) , fenofibrate repressed the expression of a CXCL10 promoter-luciferase construct, indicating that the repression of CXCL10 mRNA expression occurs at least partly by a transcriptional mechanism. TNFastimulated transcription of the CXCL10 gene is largely mediated by nuclear factor kB (NF-kB) binding to 2 kB binding sites located in the CXCL10 proximal promoter (Majumder et al. 1998) .
PPAR ligands repress transcriptional activation by NF-kB via a mechanism known as ligand-dependent transrepression (Delerive et al. 1999 , Pascual et al. 2005 ; thus, NF-kB is a likely target for repression of CXCL10 transcription by fenofibrate.
Interestingly, however, in the study by Lee et al. (2007) , all five chemokine genes tested are known to be activated by NF-kB, but two of these genes, CXCL8 (IL8) and CXCL1 (GRO1), were not repressed significantly by fenofibrate. This suggests that the promoter context and perhaps the presence or absence of corepressor complexes associated with promoters in the inactive state may determine which NF-kB-activated promoters are repressed by fenofibrate (Pascual et al. 2005) .
In addition to repressing TNFa-mediated activation of the CXCL10 promoter, fenofibrate also repressed activation of the promoter by IFNg. This repression very likely acts via IFN response factor-containing complexes that bind to the IFN-stimulated response element of the CXCL10 promoter after stimulation with IFNg (Majumder et al. 1998) .
PPARg ligands show an inhibitory activity on CXC chemokines, confirming the results of our previous studies (Antonelli et al. 2006c (Antonelli et al. , 2009a . However, the relative potency of PPARa agonists on the inhibition of the secretion of CXC chemokine is higher than that of PPARg ligands. This could suggest that PPARa agonists may act, at least in part, through different pathways than PPARg agonists (Marx et al. 2000 , Schaefer et al. 2005 , Lombardi et al. 2008 , Antonelli et al. 2009b .
The effect of PPARa agonists on CCL2 has been investigated but not in GO cells. In fact, PPARa activators suppress lipopolysaccharide-stimulated Ccl2 transcription and release in activated rat glia (Lee et al. 2005) . Furthermore, PPARa activators inhibit CCL2 expression induced by high glucose concentration in human endothelial cells (Dragomir et al. 2006) .
The results of this study show a potent inhibition (more than 60%) of the cytokine-stimulated CCL2 secretion by PPARa agonists both in normal and in GO cells. Interestingly, PPARg agonists show no effect on the secretion of CCL2 in GO cells. This discrepancy is in agreement with the results of other studies on different cells (Nie et al. 2005) . The different effects of PPARa and PPARg agonists on the secretion of chemokines in GO cells may be, at least in part, explained by the different pathways involved.
Recently, it has been demonstrated that rosiglitazone was associated with an increased risk of stroke, heart failure, and allcause mortality in elderly patients (Graham et al. 2010) , and the European Medicines Agency (EMA) recommended on September 2010 that rosiglitazone be suspended from the European market. More recently, the EMA extended the review of safety to pioglitazone (Moynihan 2011) . Even if these arguments cannot be automatically translated in GO field, they do not actually advise PPARg agonists for the therapy of GO.
The presence of PPARa in GO fibroblasts or preadipocytes and the immunomodulatory effect of PPARa agonists on the production of Th1 and Th2 chemokines suggest that PPARa may be involved in the modulation of the immune response both in normal and GO cells, probably by interaction with endogenous ligands. A therapeutic use of PPARa ligands in GO remains to be explored, but it is suggested by the fact that their effect on chemokines has been exerted at near-therapeutic doses. Despite anti-inflammatory actions of PPARa, its proadipogenic functions in the orbit might worsen the disease, contraindicating the use of these agents in GO (Pasquali et al. 2004) . Thus, further studies are necessary to establish whether in active GO the antiinflammatory effects of PPARa activation can be exploited without the risk of expanding retrobulbar fat mass, for example, combining PPARa agonists and non-steroidal antiinflammatory drugs or glucocorticoids that may synergize to exert their anti-inflammatory action.
In conclusion, this study shows that CCL2 is modulated by IFNg and TNFa in GO. PPARa activators are able to inhibit the secretion of the main prototype a (CXCL10) and b (CCL2) chemokines in GO fibroblasts or preadipocytes, suggesting that PPARa may be involved in the modulation of the immune response in GO.
Declaration of interest
